Tactical Therapeutics, Inc. United States

Dr Rashida Karmali
Dr Rashida Karmali

Tactile Navigation Tools United States

TNT (Tactile Navigation Tools, LLC) creates and commercializes superior assistive technology for those with visual impairment. Currently, the tools and devices offered are antiquated and inadequate for the challenges of the visually disabled, preventing health optimization by many. 

We have tools that simplify training, increase mobility, and permit functional independence. The founder is a disability physician living with visual impairment and the team combines rehabilitation medicine, engineering, computer modeling and psychophysics.

Todd Hudson

Takeda Pharmaceuticals United States

Based on the corporate philosophy of "Takeda-ism" (Integrity: Fairness, Honesty and Perseverance) developed over its long corporate history of more than 230 years, Takeda conducts activities according to the corporate mission to “strive towards better health for people worldwide through leading innovation in medicine.”

Daniel Kemp
Sr. Director, Center for External Innovation 

Tanner-Ibbotson, Inc. United States

Tanner-Ibbotson recognizes the importance of innovation and technological advances in Public Health.  Companies that research and manufacture medical devices, diagnostics, therapeutics and pharmaceuticals are exposed to risk at each level of development. An unexpected event can prevent the next big advancement from ever making it to the marketplace.  Life Science companies require a specialized comprehensive insurance and risk management program.  
New York State is recognized as one of the epicenters of Innovation in Life Sciences in the United States.  Tanner-Ibbotson has partnered with PRS Brokers to meet the unique and specific needs of Life Science Companies.  The partnership brings together close to 20 years experience in providing insurance and risk management solutions to the Life Science sector.
Expert knowledge of this industry enables us to tailor a program that can include:

  • Property
  • General Liability
  • Auto Liability
  • Product Liability
  • Professional Liability
  • Clinical Trials- US and Worldwide
  • Management Liability
  • Workers Compensation
  • Product Recall
  • Intellectual Property
  • Transit/Ocean Marine

We serve Life Science companies in all stages from Research & Development to clinical trials to commercialization.
The industry includes the following:

  • Medical Device Manufacturers & Distributors
  • Pharmaceutical Manufacturers & Distributors
  • Nutraceuticals/Supplements Manufacturers & Distributors
  • Biotechnology Companies
  • Medical Software Developers
  • Nanotechnology Companies
  • Contract Drug or Device Manufacturers
  • Contract Research Organizations
  • Site Management Organizations
Mr Brian Toglia
Vice President 

Technovax United States

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. 

TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! 

Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: 
- A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; 
- An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; 
- An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. 

We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.

Dr Jose Galarza
Helene Boigard
Research Associate 
Hector Munoz

The Feinstein Institute for Medical Research - The North Shore-LIJ Health System United States

Mr Chad Bouton
Division Leader, Neurotechnology and Analytic - Managing Director, Center for Bioelectronic Medicine 

The Feinstein Institute for Medical Research - The North Shore-LIJ Health System United States

Professor Christopher J. Czura
VP, Scientific Affairs - Executive Director, Merinoff Symposia - Publisher of Molecular Medicine and Bioelectronic Medicine  

The Feinstein Institute for Medical Research - The North Shore-LIJ Health System United States

Ms Carol Ann Amella
Administrative Director of the Center for Bioelectronic Medicine  

The Galien Foundation United States

The MedTech Strategist United States

The MedTech Strategist Is Here to Help You Make Sense of the Myriad Factors Impacting the Medical Device Industry – and Your Success.    – Insights that fuel your company’s growth    – Twice-monthly, smart, informed analysis of device market dynamics and trends    – Editorial content backed by unparalleled device industry experience and knowledge: Editors-in-Chief David Cassak and Stephen Levin, and their seasoned editorial team   – 22 issues published per year, more than any other device publication – and at a fraction of the cost
 – Subscribers to The MedTech Strategist include device market leaders, start-ups, investors, management consulting firms, law firms, physician entrepreneurs, engineers, and scientists, among many others with a stake in the rapidly evolving device space
Ms Wendy Diller
Senior Writer/ Analyst